TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Appropriate Risk-Benefit Assessment Helps Drug Availability

Appropriate Risk-Benefit Assessment Helps Drug Availability

Considering the on-going issues with drug shortages, which could potentially be exacerbated by Brexit, we were reminded recently by the editor of the PDA newsletter of an excellent Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products.  This perspective was published by Bukofser et al. and is attached in the link below.

PDA J Pharm Sci and Tech 2015, 69, 123-139

The expectation for safe and effective injectable drug products requires that these products are manufactured “essentially free” of extraneous matter. As we know, this is a very challenging activity and the authors highlight that between 2008-2012, particle related issues led to 22% of product recalls for injectable products. The guidance on the expectations for inspection methods and acceptance criteria for particles are described in the various Pharmacopeias: USP, EP and JP. All Pharmacopeias require that each container, where possible, is inspected and those containing particles are rejected. The inspection process must be designed and qualified to ensure each lot is “essentially free” of visible particles. The relevant chapters of the USP identify inspection conditions and quantitative limits based on acceptance sampling from each lot of injectable product. The EP and Annex 1 further define: illumination intensity, background, pace and conditions for inspection, and vision tests and break periods for inspectors. It is recognized in the Pharmacopeias that the inspection process is based on the probability of detection and it is not absolute.

The medical data to support the safety risk of particles in humans is relatively scarce and a knowledge gap exists between the inherent presence of particles in injectable products and documented adverse events resulting from inadvertent administration of particles to patients. It is suggested by the author that the lack of medical literature on the harm caused by particles in pharmaceutical products may reflect the high standards of existing sterile manufacturing processes.

It is generally acknowledged that injectable drug product availability has presented a risk to patient safety and this can in part be attributed to inconsistent product release decisions and recall decisions related to particles. In the context where there is limited availability of essential sterile injectable products, it is incumbent on patients, care providers, manufacturers and regulators to consider the risk-benefit of potentially administering injectable products containing particles to patients. This is further supported when we recognise the probabilistic nature of particle detection and limited data on adverse events resulting from the presence of particles in injectable products.

The medical risk assessment required for such a risk-benefit consideration follows ICH Quality Guideline Q9: Quality Risk Management principles. The overall risk could be considered as the [likelihood of hazard] x [severity of harm]. This could be further refined to the [likelihood of particle presence] x [(likelihood of harm) x (severity of harm)]. The likelihood of particle presence must be understood from the manufacturing process and where particles can be generated, detected and removed from the product over its life-cycle. Statistical data from inspections, manufacturing trend history, supplier incoming data and complaint data can all be used for evaluating the likelihood of particle presence. The assessment of likelihood and severity of harm must be an extensive investigation into the five P’s: the particle, the product, the path, the patient and the prevention (see table 1 below).

 

 

Table 1. The five P’s of assessing the likelihood and severity of patient harm from particles

Particle –  Size, type (intrinsic/extrinsic/inherent),

–  characteristics (shape, composition, reactivity),

–  Source

–  Quantity

Product –  Route of Administration (Subcutaneous, Intramuscular, Intravenous, Infusion, Intrathecal etc.),

–  Volume of Administration (particles per volume unit)

Path –  Likely fate of the particle in the patient (remains at site of administration, central or peripheral venous administration etc.)
Patient –  Age

–  Gender

–  Weight

–  Illness

–  Immune status

Prevention –  Particle reduction mitigation, point of filtration in manufacturing or administration

 

By combining the understanding of the likelihood of the particle hazard and the severity of the harm associated with particle presence, an overall medical risk can be established. On this basis, which is a more holistic approach to patient risk, informed decisions can be made when deciding to recall a product from the market that is potentially short in supply with little or no alternative. It is most likely that the requirement for automatic recall due to a single particle in a single unit should only occur in specific and special circumstances.

Patient harm associated with injections is extremely limited at the current levels of particle matter contained in injectable drug products. Small quantities of inert particles are unlikely to cause clinically meaningful harm to patients, in particular for intramuscular or subcutaneous routes of administration. 100% “particle free” injectable drug products should be the goal for manufacturers but not the requirement. While manufacturers strive to ensure injectable products are particle free, Bukofser et al. have succinctly outlined considerations important in assessing the risk-benefit ratio of administering products potentially containing particles to patients.

If you would like further information or wish to discuss how PharmaLex can support you with queries on Risk Analysis in Drug Product manufacture, please connect with us at +353 1 846 4742 or contactirl@pharmalex.com.

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Thanks so much for your support over the past 30 days. Your commitment and timely communication have made working with you all a pleasant experience.

    US Biotech
    Senior QA Associate
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for